RSV is the major focus.........sure, we can continue our avian and seasonal flu programs as they are built upon the new VLP technology and are very valuable. BUT, when NVAX gets to the next stage with RSV (and PATH / Gates Foundation), this is the next event to really move the needle on the share price. We will take the rise due to Avian concerns, but this might be temporary.........don't want the price overinflated due to Avian. Want it to rise appreciably due to next event with RSV. This is more sustainable, stable and better for shareholders.